Lilly, Boehringer collaborate on diabetes drugs

January 11, 2011

(AP) -- Eli Lilly will pay Boehringer Ingelheim $387.4 million and collaborate with the German drugmaker to develop diabetes drugs with the U.S. pharmaceutical company facing the expiration of some of its key patents.

Lilly, based in Indianapolis, loses this year for its top-selling drug, the anti-psychotic Zyprexa, and faces the loss of some other key patents in the next few years. The drugmaker said Tuesday that the deal with Boehringer Ingelheim offers the potential of boosting near-term revenue.

Lilly could receive more than $1 billion in future payments depending on how well the collaboration performs and whether the drugs under development reach certain sales milestones. Boehringer Ingelheim will be eligible for future payments totaling about $807 million.

The collaboration includes two Lilly insulins expected to enter late-stage testing this year and a treatment from Boehringer Ingelheim that is being reviewed by regulators.

Shares of Eli Lilly and Co. rose slightly in premarket trading.

Explore further: Mississippi sues pharmaceutical company

0 shares

Related Stories

Mississippi sues pharmaceutical company

July 25, 2006

Mississippi has filed a legal action against Eli Lilly and Co. alleging a plan to defraud the state of millions of dollars in Medicaid reimbursements.

Mississippi sues pharmaceutical company

July 25, 2006

Mississippi has filed a legal action against Eli Lilly and Co. alleging a plan to defraud the state of millions of dollars in Medicaid reimbursements.

FDA clears Eli Lilly's blood thinner Effient

July 10, 2009

(AP) -- The Food and Drug Administration on Friday approved a highly anticipated blood thinner from Eli Lilly, though the drug must carry the agency's sternest warning because of its bleeding risks.

Eli Lilly halts development of Alzheimer's drug

August 17, 2010

(AP) -- Eli Lilly and Co. has stopped developing a potential Alzheimer's disease treatment at a time when the drugmaker is searching wide and far for new drugs to fill a large revenue hole that will form starting next year.

German firm shelves libido-boosting drug for women

October 9, 2010

German drug firm Boehringer Ingelheim has shelved development of a libido-booster for women after it was given the thumbs down by the US Food and Drug Administration (FDA), the company said.

Recommended for you

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

(PhysOrg.com) -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...

Quantum Theory May Explain Wishful Thinking

April 14, 2009

(PhysOrg.com) -- Humans don’t always make the most rational decisions. As studies have shown, even when logic and reasoning point in one direction, sometimes we chose the opposite route, motivated by personal bias or simply ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

DanielHaszard
not rated yet Jan 11, 2011
Zyprexa damage Claims Still Unresolved-

Eli Lilly's #1 cash cow Zyprexa drug sale $38 billion dollars to date has a greater risk of causing type 2 diabetes over the non-user of Zyprexa. So,here we have a conflict of interest that this same company also is a big profiteer of diabetes treatment.

All the best for Eli Lilly and resolution of Zyprexa claims
--Daniel Haszard Zyprexa victim activist


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.